Nucleotide Metabolism and Antimetabolites
Two Routes, One Pool
| Route | Enzymes | Substrates | Note |
|---|---|---|---|
| Purine de novo | PRPP → IMP; ATIC, GART, PAICS, ADSL | Ribose-5-phosphate, amino acids, formate, CO₂ | Consumes one-carbon units heavily |
| Pyrimidine de novo | CAD, DHODH, UMPS | Glutamine, CO₂, aspartate | DHODH is mitochondrial |
| Purine salvage | HPRT, APRT, PNP | Free bases | Low energy cost |
| Pyrimidine salvage | TK1, UCK, dCK | Nucleosides | TK1 is cell-cycle regulated |
| Reduction | RRM1/RRM2 | NDP → dNDP | Rate-limiting for DNA synthesis |
Important distinction. De novo synthesis and salvage converge on the same nucleotide pool, and cells differ widely in which they rely on. A tumour line with high salvage capacity can be insensitive to a de novo pathway inhibitor, not because the pathway is unimportant but because it is not limiting.
Part 1 — What Antimetabolites Test
| Drug | Target | What resistance reveals |
|---|---|---|
| Methotrexate | DHFR; also thymidylate and purine synthesis | Folate transport; DHFR amplification; reduced polyglutamation |
| 5-Fluorouracil | Thymidylate synthase; also RNA incorporation | TS amplification; decreased activation; increased catabolism |
| Gemcitabine | Ribonucleotide reductase; DNA incorporation | dCK deficiency; RRM overexpression |
| Hydroxyurea | Ribonucleotide reductase | RR subunits; dNTP pool status |
| Leflunomide / brequinar | DHODH | Pyrimidine salvage capacity |
| 6-Mercaptopurine | HPRT-dependent incorporation | HPRT loss; TPMT activity |
Readout note. Each of these drugs is a probe of one step, and the phenotype reports both the step and the cell's ability to compensate. A resistance phenotype therefore needs to distinguish "target changed" from "compensation increased" — a distinction that requires measuring the nucleotide pool, not only the drug response.
Part 2 — The dNTP Pool and Its Imbalance
| Imbalance | Cause | Consequence |
|---|---|---|
| dATP excess | ADA deficiency; dATP accumulation | Ribonucleotide reductase inhibition; immunodeficiency |
| dTTP excess | TS inhibition; excess thymidine | Feedback inhibition; replication stress |
| dCTP depletion | CTP synthetase inhibition | Replication stress; DNA damage |
| General dNTP reduction | RR inhibition | Replication slowdown; S-phase arrest |
| Purine excess | HPRT deficiency | Salvage imbalance; gout; neurological features |
Important distinction. Nucleotide pools are not a single quantity. A "nucleotide depletion" measured as total ATP says nothing about dNTPs, which are three to four orders of magnitude less abundant and are the ones that limit replication. Measuring the wrong pool is a common reason a plausible antimetabolite mechanism is not supported.
Part 3 — Coupling to One-Carbon and Amino Acid Metabolism
Nucleotide synthesis is where the amino acid and one-carbon pillars meet.
| Requirement | Source | Consequence of limitation |
|---|---|---|
| Ribose-5-phosphate | Pentose phosphate pathway | Reduced PRPP; impaired both purine and pyrimidine synthesis |
| Formate (10-formyl-THF) | Serine via mitochondrial one-carbon | Impaired purine synthesis; the basis of formate dependency |
| Glutamine amide nitrogen | Glutaminolysis | Impaired both purine and pyrimidine synthesis |
| Aspartate | Transamination; mitochondrial oxidation | Impaired pyrimidine synthesis; a documented respiration dependency |
| Glycine | Serine cleavage; uptake | Purine synthesis |
Caveat on the aspartate story. Aspartate is produced in mitochondria and used in the cytosol, and its export depends on the respiratory chain through the malate–aspartate shuttle. This is why electron transport inhibition can limit proliferation through nucleotide synthesis rather than through ATP — a mechanism that an ATP measurement alone would miss.
Part 4 — Measuring the Pool
| Measurement | Reports | Requirement |
|---|---|---|
| NTP by LC-MS | Ribonucleotide pools | Immediate quench; ion-pairing chromatography |
| dNTP by LC-MS or enzymatic assay | Deoxyribonucleotide pools | Sensitive method; low abundance |
| ¹³C or ¹⁵N labelling into nucleotides | Synthesis rate | Position-specific tracers; timecourse |
| Nucleoside salvage | Route capacity | Labelled nucleoside incorporation |
| Pool size after drug treatment | Target engagement plus compensation | Matched timepoints |
Readout note. Nucleotide extraction must be fast and cold: ATP degrades within minutes at room temperature, and phosphatase activity continues after harvest. An extraction that takes ten minutes produces a pool profile that reflects the extraction, not the cell.
Part 5 — Where the Demand Comes From
A nucleotide pool is the difference between synthesis and consumption, and consumption is often the variable that changed.
| Demand | Timescale | Consequence of an increase |
|---|---|---|
| Genome replication | S phase | dNTP demand rises sharply and transiently |
| DNA repair | Minutes to hours | Localised dNTP consumption; PARP activation depletes NAD⁺, not nucleotides directly |
| RNA synthesis and turnover | Minutes | NTP demand, largely buffered |
| Mitochondrial DNA replication | Continuous | Separate dNTP pool; depends on the same salvage enzymes |
| NAD⁺ synthesis | Continuous | Competes for the same adenylate precursor |
Important distinction. A fall in a nucleotide pool can reflect reduced supply or increased demand, and the two have opposite implications for a drug combination. Reduced supply suggests the synthetic route is limiting; increased demand suggests the cell is replicating or repairing faster, which is often the intended effect of a cytotoxic agent.
The fourth row is the one most often overlooked: mitochondrial dNTP pools are maintained separately, and a drug that depletes cytosolic dNTPs can leave mitochondrial replication intact — or, in the case of some nucleoside analogues, the reverse. A claim about "nucleotide depletion" should state which pool.
Readout note. Measuring the pool at a single timepoint cannot separate supply from demand. A labelling measurement — precursor incorporation over a short window — reports synthesis, and comparing it with the pool size reports the balance. This is the same pool-versus-flux distinction that applies throughout this domain, and it applies here with a particular trap: nucleotide pools are small and turn over fast, so a change in demand can change the pool within an hour.
Part 6 — Model Requirements and Recurring Failures
| Requirement | Why |
|---|---|
| Nucleoside concentration in medium stated | Serum and medium supply salvage substrates |
| Dialysed serum documented | Removes nucleosides; changes salvage dependence |
| Proliferation rate measured | Determines de novo demand |
| Salvage capacity considered | Explains resistance without target change |
| Pool compartment noted | Cytosolic versus mitochondrial |
| Timepoint matched to the mechanism | Pool depletion precedes DNA damage |
Recurring failures:
- • Total ATP reported as "nucleotide pool".
- • dNTP measured without immediate quench.
- • Resistance attributed to the target when salvage capacity increased.
- • Nucleosides in serum unrecorded, so salvage capacity is undefined.
- • De novo synthesis measured without labelling, using enzyme expression instead.
- • One-carbon and glutamine supply ignored, although both limit synthesis.
- • Drug effect measured at a single late timepoint, after secondary DNA damage.
Part 7 — Where This Article Connects
This is the consumer article of the amino acid cluster: purines and pyrimidines are where formate, glutamine amide nitrogen, glycine and aspartate converge. It connects to the serine–glycine article for one-carbon supply, to the glutaminolysis article for amide nitrogen, and to the glucose pillar for ribose-5-phosphate through the pentose phosphate pathway.
If you need nucleotide pools measured with immediate quench and route-resolved labelling, we can scope the analysis with you.
Contact EDITGENE to request a project consultation or quote.
Scientific scope and validation note
De novo synthesis, salvage capacity and drug sensitivity vary with cell type, medium nucleosides, proliferation rate and transporter expression. The patterns here are conditional.
A drug response does not identify the step affected, and a pool change does not establish a change in synthesis rate.
Scientific interpretation and experimental design
- • Two routes to one pool. Salvage explains resistance.
- • NTP is not dNTP. Different abundance, different meaning.
- • Immediate quench. ATP degrades in minutes.
- • Nucleosides in serum matter. They define salvage capacity.
- • One-carbon and glutamine are upstream. Both limit synthesis.
- • Aspartate links respiration to proliferation.
Selected references for further reading
- • Lane AN, Fan TW. Regulation of mammalian nucleotide metabolism and biosynthesis. Nucleic Acids Research. 2015;43:2466–2485.
- • Sullivan LB, et al. Supporting aspartate biosynthesis is an essential function of respiration in proliferating cells. Cell. 2015;162:552–563.
- • Villa E, et al. Cancer cells tune the signaling pathways to empower de novo synthesis of nucleotides. Cancers. 2019;11:688.
- • Ben-Sahra I, et al. mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle. Science. 2016;351:728–733.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »